Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Stock Holdings Lifted by Fmr LLC

Fmr LLC raised its position in shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) by 33.0% in the third quarter, Holdings Channel reports. The firm owned 10,028 shares of the biopharmaceutical company’s stock after buying an additional 2,486 shares during the period. Fmr LLC’s holdings in Corbus Pharmaceuticals were worth $207,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Darwin Global Management Ltd. acquired a new position in Corbus Pharmaceuticals in the second quarter worth approximately $14,267,000. Integral Health Asset Management LLC acquired a new position in shares of Corbus Pharmaceuticals during the 2nd quarter worth $4,525,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Corbus Pharmaceuticals by 224.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 93,643 shares of the biopharmaceutical company’s stock valued at $1,932,000 after purchasing an additional 64,800 shares in the last quarter. HealthInvest Partners AB lifted its stake in shares of Corbus Pharmaceuticals by 77.9% in the 3rd quarter. HealthInvest Partners AB now owns 69,573 shares of the biopharmaceutical company’s stock valued at $1,435,000 after purchasing an additional 30,473 shares during the last quarter. Finally, TD Asset Management Inc boosted its holdings in Corbus Pharmaceuticals by 92.5% in the second quarter. TD Asset Management Inc now owns 40,800 shares of the biopharmaceutical company’s stock worth $1,846,000 after purchasing an additional 19,600 shares in the last quarter. 64.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Piper Sandler started coverage on Corbus Pharmaceuticals in a research report on Monday, December 2nd. They issued an “overweight” rating and a $35.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Corbus Pharmaceuticals in a report on Monday, September 23rd. Mizuho reaffirmed an “outperform” rating and set a $74.00 target price on shares of Corbus Pharmaceuticals in a research report on Friday, September 20th. Wedbush reissued an “outperform” rating and issued a $51.00 price target on shares of Corbus Pharmaceuticals in a research report on Monday, November 4th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $82.00 price objective on shares of Corbus Pharmaceuticals in a report on Friday, September 20th. One analyst has rated the stock with a sell rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $62.00.

Corbus Pharmaceuticals Price Performance

Shares of Corbus Pharmaceuticals stock opened at $13.00 on Friday. The company has a market cap of $158.33 million, a PE ratio of -2.77 and a beta of 2.57. The firm has a fifty day moving average price of $16.85 and a two-hundred day moving average price of $36.54. Corbus Pharmaceuticals Holdings, Inc. has a fifty-two week low of $5.09 and a fifty-two week high of $61.90.

Corbus Pharmaceuticals Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.